Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: Randomised controlled trial

BMJ (Online)

Volumn 341, Issue 7785, 2010, Pages 1262-

  Aaby, Peter ^a,b   Martins, Cesário L ^a   Garly, May Lill ^a,b   Balé, Carlito ^a   Andersen, Andreas ^a,b   Rodrigues, Amabelia ^a   Ravn, Henrik ^a,b   Lisse, Ida M ^c   Benn, Christine S ^a,b   Whittle, Hilton C ^d  

^a Studies of the Epidemiology of Epilepsy in Demographic Surveillance Systems   (Guinea-Bissau)

^b DEPARTMENT OF EPIDEMIOLOGY RESEARCH   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; MEASLES VACCINE; RETINOL;

ARTICLE; CHILD; CHILDHOOD MORTALITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOSAGE SCHEDULE COMPARISON; DRUG EFFECT; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEASLES; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEASONAL VARIATION; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; SURVIVAL; TREATMENT OUTCOME;

AGE FACTORS; CHILD, PRESCHOOL; DIETARY SUPPLEMENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFANT; INFANT MORTALITY; KAPLAN-MEIER ESTIMATE; MALE; MEASLES; MEASLES VACCINE; URBAN HEALTH; VITAMIN A; VITAMINS;

EID: 78649996830     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c6495     Document Type: Article

References (56)

1. Kasongo Project Team. Influence of measles vaccination on survival pattern of 7-35-month-old children in Kasongo, Zaire. Lancet 1981;1:764-7.
2. Aaby P, Bukh J, Lisse IM, Smits AJ. Measles vaccination and child mortality. Lancet 1981;ii:93.
3. Aaby P, Bukh J, Lisse IM, Smits AJ. Measles vaccination and reduction in child mortality: a community study from Guinea-Bissau. J Infect 1984;8:13-21. (Pubitemid 14223302)
4. Desgrées du Loû A, Pison G, Aaby P. The role of immunizations in the recent decline in childhoodmortality and the changes in the female/ male mortality ratio in rural Senegal. Am J Epidemiol 1995;142:643-52.
5. Aaby P, Samb B, Simondon F, Knudsen K, Coll Seck AM, Bennett J, et al. Divergent mortality for male and female recipients of low-titre and high-titre measles vaccines in rural Senegal. Am J Epidemiol 1993;138:746-55. (Pubitemid 23339017)
6. Aaby P, Bukh J, Lisse IM, Smits AJ, Gomes J, Fernandes MA, et al. Determinants of measles mortality in a rural area of Guinea-Bissau: crowding, age, and malnutrition. J Trop Pediatr 1984;30:164-9.
7. Aaby P, Pedersen IR, Knudsen K, da Silva MC, Mordhorst CH, Helm-Petersen NC, et al. Child mortality related to seroconversion or lack of seroconversion after measles vaccination. Pediatr Infect Dis J 1989;8:197-200.
8. Holt EA, Boulos R, Halsey NA, Boulos IM, Boulos C. Childhood survival in Haiti: protective effect of measles vaccination. Pediatrics 1990;85:188-94.
9. Clemens JD, Stanton BF, Chakraborty J, Chowdhury S, Rao M, Ali M. Measles vaccination and childhood mortality in rural Bangladesh. Am J Epidemiol 1988;128;1330-9. (Pubitemid 19015505)
10. Koenig MA, Khan MA, Wojtyniak B, Clemens JD, Chakraborty J, Fauveau V, et al. The impact of measles vaccination upon childhood mortality in Matlab, Bangladesh. Bull World Health Organ 1990;68:441-7. (Pubitemid 20295573)
11. Aaby P, Samb B, Simondon F, Coll Seck AM, Knudsen K, Whittle H. Non-specific beneficial effect of measles immunisation: analysis of mortality studies from developing countries. BMJ 1995;311:481-5.
12. Expanded Programme on Immunisation. The optimal age for measles immunization. Wkly Epidemiol Rec 1982;57:89-91.
13. Whittle H, Hanlon P, O'Neill K, Hanlon L, Marsh V, Jupp E, etal. Trial of high-dose Edmonston-Zagreb measles vaccine in the Gambia: antibody response and side-effects. Lancet 1988;2:811-4.
14. Whittle H, Campbell H, Rahman S, Armstrong JRM. Antibody persistence in Gambian children after high-dose Edmonston-Zagreb measles vaccine. Lancet 1990;336:1048-51.
15. Aaby P, Jensen TG, Hansen HL, Kristiansen H, Thårup J, Poulsen A, et al. Trial of high-dose Edmonston-Zagreb measles vaccine in Guinea-Bissau: protective efficacy. Lancet 1988;2:809-11.
16. Aaby P, Knudsen K, Whittle H, Lisse IM, Thårup J, Poulsen A, et al. Long-term survival after Edmonston-Zagreb measles vaccination in Guinea-Bissau: increased female mortality rate. J Pediatr 1993;122:904-8.
17. Aaby P, Samb B, Simondon F, Knudsen K, Coll Seck AM, Bennett J, et al. Sex-specific differences in mortality after high titre measles immunization in rural Senegal. Bull World Health Organ 1994;72:761-70. (Pubitemid 24344101)
18. Knudsen KM, Aaby P, Whittle H, Rowe M, Samb B, Simondon F, et al. Child mortality following standard, medium or high titre measles immunization in West Africa. Int J Epidemiol 1996;25:665-73. (Pubitemid 27018298)
19. Aaby P, Jensen H, Samb B, Cisse B, Sodeman M, Jakobsen M, et al. Differences in female-male mortality after high-titre measles vaccine and association with subsequent vaccination with diphtheria-tetanus- pertussis and inactivated poliovirus: reanalysis of West African studies. Lancet 2003;361:2183-8.
20. Holt EA, Moulton LH, Siberry GK, Halsey NA. Differential mortality measles vaccine titer and sex. J Infect Dis 1993;168:1987-96.
21. Expanded Programme on Immunization. Safety of high titre measles vaccines. Wkly Epidemiol Rec 1992;67:357-61.
22. Garly ML, Martins CL, Balé C, da Costa F, Dias F, Whittle H, et al. Early two-dose measles vaccination schedule in Guinea-Bissau: good protection and coverage in infancy. Int J Epidemiol 1999;28:347-52. (Pubitemid 29176667)
23. Garly ML, Balé C, Martins C, Monteiro M, George E, Kidd M, et al. Measles antibody responses after early two dose trials in Guinea- Bissau with Edmonston-Zagreb and Schwarz standard-titre measles vaccine: better antibody increase from booster dose of the Edmonston-Zagreb vaccine. Vaccine 2001;19:1951-9.
24. Aaby P, Garly ML, Balé C, Martins C, Jensen H, Lisse IM, et al. Survival of previously measles-vaccinated and measles-unvaccinated children in an emergency situation: an unplanned study. Pediatr Infect Dis J 2003;22:798-805. (Pubitemid 37153074)
25. Aaby P, Garly ML, Jensen H, Martins C, Balé C, Benn CS, et al. Inactivated polio and diphtheria-tetanus-pertussis vaccines associated with increased female mortality prior to measles vaccination: observations from vaccination trials in Guinea-Bissau. Pediatr Infect Dis J 2007;26:247-52. (Pubitemid 46340773)
26. Martins CL, Garly ML, Balé C, Rodrigues A, Ravn H, Whittle HC, et al. Protective efficacy of standard Edmonston-Zagreb measles vaccination in infants aged 4.5 months: interim analysis of a randomised clinical trial. BMJ 2008;337:a661.
27. Martins C, Bale C, Garly ML, Rodrigues A, Lisse IM, Andersen A, et al. Girls may have lower levels of maternal measles antibodies and higher risk of subclinical measles infection before the age of measles vaccination. Vaccine 2009;27:5220-5.
28. Aaby P. Bandim: an unplanned longitudinal study. In: Das Gupta M, Aaby P, Pison G, Garenne M, eds. Prospective community studies in developing countries. Oxford University Press, 1997:276-96.
29. Aaby P, Martins C, Bale C, Garly ML, Rodrigues A, Biai S, et al. Sex differences in the effect of vaccines on the risk of hospitalisation due to measles in Guinea-Bissau. Pediatr Infect Dis J 2010;29:324-8.
30. Benn CS, Fisker A, Roth A, Diness BR, Lausch KR, Ravn H, et al. Randomised trial of vitamin A supplementation and BCG vaccination at birth to low-birth-weight children. BMJ 2010;340:c1101.
31. Benn CS, Diness BR, Roth A, Nante E, Fisker AB, Lisse IM, et al. Effect of 50,000 IU vitamin A given with BCG vaccine onmortality in infants in Guinea-Bissau: randomised placebo controlled trial. BMJ 2008;336:1416-20.
32. Benn CS, Rodrigues A, Yazdanbakhsh M, Fisker AB, Ravn H, Whittle H, et al. The effect of high-dose vitamin A supplementation administered with BCG vaccine at birth may be modified by subsequent DTP vaccination. Vaccine 2009;27:2891-8.
33. Aaby P, Samb B, Simondon F, Cisse B, Jensen H, Lisse IM, et al. Low mortality after mild measles infection compared to uninfected children in rural West Africa. Vaccine 2002;21:120-6.
34. Aaby P, Bhuyia A, Nahar L, Knudsen K, Francisco A, Strong M. The survival benefit of measles immunisation may not be explained entirely by the prevention of measles disease. Int J Epidemiol 2003;32:106-15.
35. Garly ML, Trautner SL, Marx C, Danebod K, Nielsen J, Ravn H, et al. Thymus size at 6 months of age and subsequent child mortality. J Pediatr 2008;153:683-8.
36. Aaby P, Jensen H, Walraven G. Age-specific changes in female-male mortality ratio related to the pattern of vaccinations: an observational study from rural Gambia. Vaccine 2006;24:4701-8.
37. Aaby P, Vessari H, Nielsen J, Maleta K, Benn CS, Jensen H, et al. Non-specific and sex-differential effects of routine immunizations in rural Malawi. Pediatr Infect Dis J 2006;25:721-7. (Pubitemid 44162130)
38. Aaby P, Benn CS. Assessment of childhood immunisation coverage? Lancet 2009;373:1428.
39. Bennett JV, Cutts FT, Katz SL. Edmonston-Zagreb measles vaccine: a good vaccine with an image problem. Pediatrics 1999;104:1123-4.
40. Aaby P, Ibrahim S, Libman M, Jensen H. The sequence of vaccinations and increased female mortality after high-titre measles vaccine: trials from rural Sudan and Kinshasa. Vaccine 2006;24:2764-71.
41. Aaby P, Andersen M, Sodemann M, Jakobsen M, Gomes J, Fernandes M. Reduced childhood mortality after standard measles vaccination at 4-8 months compared with 9-11 months of age. BMJ 1993;307:1308-11. (Pubitemid 23337746)
42. Benn CB, Martins C, Rodrigues A, Fisker AB, Christoffersen D, Aaby P. The effect of vitamin A supplementation administered with missing vaccines during national immunisation days in Guinea-Bissau. Int J Epidemiol 2009;38:304-11.
43. Benn CS, Aaby P, Nielsen J, Binka FN, Ross DA. Does vitamin A supplementation interact with routine vaccinations? An analysis of the Ghana vitamin A supplementation trial. Am J Clin Nutr 2009;90:629-39.
44. Roth A, Benn CB, Ravn H, Rodrigues A, Lisse IM, Yazdanbakhsh M, et al. A randomised trial of the effect of revaccination with BCG in early childhood and mortality. BMJ 2010;340:c809.
45. Cooper WO, Boyce TG, Wright PF, Griffin MR. Do childhood vaccines have non-specific effects on mortality? Bull World Health Organ 2003;81:821-6.
46. Aaby P, Lisse I, Mølbak K, Knudsen K, Whittle H. No persistent T lymphocyte immunosuppression or increased mortality after measles infection: a community study from Guinea-Bissau. Pediatr Infect Dis J 1996;15:39-44. (Pubitemid 26029242)
47. Aaby P, Samb B, Andersen M, Simondon F. No long-term excess mortality after measles infection: a community study from Senegal. Am J Epidemiol 1996;143:1035-41. (Pubitemid 26140331)
48. Veirum JE, Sodemann M, Biai S, Jakobsen M, Hedegaard K, Jensen H, et al. Routine vaccinations associated with divergent effects on female and male mortality at the paediatric ward in Bissau, Guinea- Bissau. Vaccine 2005;23:1197-204. (Pubitemid 40052016)
49. Shann F. Heterologous immunity and the non-specific effects of vaccines: a major medical advance? Pediatr Infect Dis J 2004;23:555-8.
50. Welsh RM, Selin LH. No one is naïve: the significance of heterologus T-cell immunity. Nat Rev Immunol 2002;2:417-26.
51. Lindblad EB, Elhay MJ, Silva R, Appelberg R, Andersen P. Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect Immun 1997;65:623-9. (Pubitemid 27053234)
52. Barnard A, Mahon BP, Watkins J, Redhead K, Mills KH. Th1/Th2 cell dichotomy in acquired immunity to Bordetella pertussis: variables in the in vivo priming and in vitro cytokine detection techniques affect the classification of T-cell subsets as Th1, Th2 or Th0. Immunology 1996;87:372-80.
53. Graham BS, Henderson GS, Tang YW, Lu X, Neuzil KM, Colley DG. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol 1993;151:2032-40.
54. Fischer JE, Johnson JE, Johnson TR, Graham BS. Pertussis toxin sensitization alters the pathogenesis of subsequent respiratory syncytial virus infection. J Infect Dis 2000;182:1029-38.
55. Moran TM, Park H, Fernandez-Sesma, Schulman JL. Th2 responses to inactivated Influenza virus can be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection. J Infect Dis 1999;180:579-85. (Pubitemid 29411340)
56. Meeting of Global Advisory Committee on Vaccine Safety, 18-19 June 2008. Wkly Epidemiol Rec 2008;83:287-92.